RTS,S/AS01E与RTS,S/AS01B延迟分次剂量方案在疟疾初治成人中的IIa期控制性人类疟疾感染与免疫原性研究
本研究将130名疟疾初治成人随机分5组,比较RTS,S/AS01B或AS01E不同延迟分次剂量方案的疫苗效力(VE)。免疫后3个月进行控制性人类疟疾感染挑战,3剂方案VE为55%至76%,2剂方案VE为29%,所有方案耐受良好且具免疫原性。
要点
- 3剂延迟分次方案VE为55%至76%,2剂方案VE较低为29%。
- RTS,S/AS01E与RTS,S/AS01B等效制剂VE可比。
- 所有方案耐受良好,保护者抗环子孢子抗体滴度呈较高趋势。
核心结论
- RTS,S/AS01E在成人中可提供与等效RTS,S/AS01B方案相当的VE,提示可考虑通用制剂。
- 2剂方案劣于所评估的3剂方案。
研究设计与样本
- IIa期随机对照试验,共130名疟疾初治成人随机分5组。
- 四组按0-1-7月程序接种3剂RTS,S/AS01B或RTS,S/AS01E,末1或2剂为五分之一剂量分次。
- 一组仅接种1剂全程(0月)加1剂分次(7月)RTS,S/AS01E。
- 免疫后3个月进行恶性疟原虫感染蚊虫挑战(控制性人类疟疾感染)。
主要发现
- 3剂方案VE范围为55%(95%CI 27%-72%)至76%(95%CI 48%-89%)。
- RTS,S/AS01E与RTS,S/AS01B等效制剂VE相当。
- 2剂方案VE为29%(95%CI 6%-46%)。
- 所有方案耐受良好且具免疫原性,保护者抗环子孢子抗体滴度呈较高趋势。
临床怎么用
- 成人疟疾预防可考虑RTS,S/AS01E的3剂延迟分次方案,VE与AS01B等效制剂可比。
- 2剂方案VE较低,不宜替代所评估的3剂方案。
局限性
- 挑战时间为免疫后3个月,长期保护效力未评估。
- 样本量为130人,分组后各组样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A previous RTS,S/AS01B vaccine challenge trial demonstrated that a 3-dose (0-1-7-month) regimen with a fractional third dose can produce high vaccine efficacy (VE) in adults challenged 3 weeks after vaccination. This study explored the VE of different delayed fractional dose regimens of adult and pediatric RTS,S/AS01 formulations. METHODS: A total of 130 participants were randomized into 5 groups. Four groups received 3 doses of RTS,S/AS01B or RTS,S/AS01E on a 0-1-7-month schedule, with the final 1 or 2 doses being fractional (one-fifth dose volume). One group received 1 full (month 0) and 1 fractional (month 7) dose of RTS,S/AS01E. Immunized and unvaccinated control participants underwent Plasmodium falciparum-infected mosquito challenge (controlled human malaria infection) 3 months after immunization, a timing chosen to potentially discriminate VEs between groups. RESULTS: The VE of 3-dose formulations ranged from 55% (95% confidence interval, 27%-72%) to 76% (48%-89%). Groups administered equivalent formulations of RTS,S/AS01E and RTS,S/AS01B demonstrated comparable VE. The 2-dose group demonstrated lower VE (29% [95% confidence interval, 6%-46%]). All regimens were well tolerated and immunogenic, with trends toward higher anti-circumsporozoite antibody titers in participants protected against infection. CONCLUSIONS: RTS,S/AS01E can provide VE comparable to an equivalent RTS,S/AS01B regimen in adults, suggesting a universal formulation may be considered. Results also suggest that the 2-dose regimen is inferior to the 3-dose regimens evaluated. CLINICAL TRIAL REGISTRATION: NCT03162614.
引用
- Moon JE, Ockenhouse C, Regules JA, et al. A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults. J Infect Dis. 2020. PMID: 32687161. doi:10.1093/infdis/jiaa421
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。